阿米万他单抗经EGFR与MET结合诱导间皮瘤免疫介导细胞毒作用
本研究基于EGFR与MET在弥漫性胸膜间皮瘤(DPM)中常表达的报道,系统评估两者共表达情况,并在临床前模型中检测双特异性抗体阿米万他单抗的活性。转录组与单细胞测序显示EGFR与MET主要在恶性细胞中共表达,免疫组化证实各组织学亚型均有蛋白表达。体外阿米万他单抗优先结合DPM细胞、抑制配体诱导信号并促进受体内化,经NK细胞介导的ADCC产生剂量依赖性细胞毒作用;在人NK细胞重建的免疫缺陷小鼠PDX模型中,阿米万他单抗联合NK细胞显著抑制肿瘤生长且无明显毒性。
要点
- EGFR与MET在DPM恶性细胞中频繁共表达,并经免疫组化证实于各组织学亚型。
- 阿米万他单抗体外经NK细胞介导ADCC产生剂量依赖性细胞毒作用。
- PDX模型中阿米万他单抗联合NK细胞显著缩小肿瘤且无明显毒性。
核心结论
- 阿米万他单抗在间皮瘤中展现稳健的临床前抗肿瘤活性,主要经EGFR与MET结合相关的固有免疫介导细胞毒作用实现。
- 上述发现支持在间皮瘤中开展靶向EGFR/MET双特异性抗体的临床评估。
研究设计与样本
- 临床前研究:采用转录组分析、免疫组化与生化实验评估患者队列及细胞系中EGFR与MET表达。
- 体外用外周血单个核细胞与自然杀伤(NK)细胞共培养体系评估受体内部化、信号阻断与免疫介导细胞毒作用。
- 体内在植入人NK细胞的免疫缺陷小鼠间皮瘤患者来源异种移植(PDX)模型中评估疗效。
主要发现
- DPM患者队列的转录组与单细胞RNA测序显示EGFR与MET频繁共表达,且主要见于恶性细胞。
- 免疫组化分析证实EGFR与MET蛋白在间皮瘤各组织学亚型中表达。
- 体外阿米万他单抗优先结合DPM细胞,抑制配体诱导的EGFR与MET信号并促进受体内部化。
- 共培养实验显示阿米万他单抗经NK细胞介导的抗体依赖性细胞毒作用(ADCC)诱导剂量依赖性细胞毒作用。
- 多个间皮瘤PDX模型中阿米万他单抗联合NK细胞显著缩小肿瘤生长且无明显毒性。
临床怎么用
- 提示EGFR/MET双特异性抗体可作为DPM的潜在靶向策略,支持进一步临床研究。
- 临床前数据尚不能直接转化为用药推荐,需等待临床试验验证。
- EGFR与MET共表达检测或可作为未来 clinical 研究的患者分层依据。
局限性
- 研究为临床前体外与动物模型研究,尚缺乏人体临床疗效与安全性数据。
- 体内实验使用免疫缺陷小鼠重建人NK细胞,与人体肿瘤免疫微环境存在差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Diffuse pleural mesothelioma (DPM) is a lethal malignancy with no approved therapies directly targeting tumor cells. Based on reports that EGFR and MET are frequently expressed in DPM, we sought to systematically assess their co-expression and determine the preclinical activity of amivantamab, a bispecific antibody that targets EGFR and MET. METHODS: We evaluated EGFR and MET expression in patient cohorts and cell lines using transcriptomic analysis, immunohistochemistry, and biochemical assays. The mechanistic actions of amivantamab, including receptor internalization, signaling blockade, and immune-mediated cytotoxicity, were assessed using in vitro co-culture systems with peripheral blood mononuclear cells and natural killer (NK) cells. In vivo efficacy was evaluated in mesothelioma patient-derived xenograft models using immunodeficient mice reconstituted with human NK cells. RESULTS: Transcriptomic and single-cell RNA-sequencing analyses of DPM patient cohorts revealed frequent co-expression of EGFR and MET, predominantly in malignant cells. Immunohistochemical analyses confirmed EGFR and MET protein expression across mesothelioma histologic subtypes. In vitro, amivantamab preferentially bound to DPM cells, inhibited ligand-induced EGFR and MET signaling, and promoted receptor internalization. Co-culture experiments demonstrated that amivantamab induced dose-dependent cytotoxicity through NK cell-mediated antibody-dependent cellular cytotoxicity. In multiple mesothelioma patient-derived xenograft models, the combination of amivantamab and NK cells significantly reduced tumor growth without overt toxicity. CONCLUSIONS: Amivantamab demonstrates robust preclinical antitumor activity in mesothelioma, primarily through innate immune-mediated cytotoxicity associated with EGFR and MET engagement. These findings support the clinical evaluation of bispecific EGFR/MET-targeting antibodies in mesothelioma.
引用
- Suzuki S, Parikh K, Tolosa E, et al. Amivantamab Induces Immune-Mediated Cytotoxicity in Mesothelioma Through EGFR and MET Engagement. J Thorac Oncol. 2026. PMID: 42323111. doi:10.1016/j.jtho.2026.103993
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。